Poster: Shi, Y.;  Dan, Y.;  Hong, Y.;  Guo, J.;  Zhao, S.;  Zeng, X.;  Hu, P.;  Jiang, W.;  Liu, S.;  Zhang, X.;  Luk, A.;  Chai, K.; Liu, E., A new population model validated pharmacokinetic similarity of HLX01 and rituximab in B-cell lymphoma. Annals of Oncology 2019, 30.

Oral: Shi, Y.; Qin, Y.; Zhao, S.; Hu, P.; Zeng, X.; Zhang, X.; Jiang, W.; Liu, S.; Liu, E.; Chai, K.; Luk, A.; Yao, D., 266OA population pharmacokinetic model: Assessment of pharmacokinetic similarity of HLX01 and rituximab in diffuse large B-cell lymphoma. Annals of Oncology 2019, 30 (suppl_9), mdz427.

Poster: Sun J, Chen G, Wu M, et al. FRI0086 CHINA-MANUFACTURED ADALIMUMAB BIOSIMILAR, HLX03, DEMONSTRATED PHARMACOKINETIC EQUIVALENCE AND COMPARABLE SAFETY TO REFERENCE ADALIMUMAB. In: BMJ Publishing Group Ltd; 2019.

Poster: Hou M, Ho C, Lin H, et al. 68P A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck. 2019;30(Supplement_9):mdz420. 007.

Chao T, Ho C, Cheng W, et al. 324P A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy. 2019;30(Supplement_9):mdz438. 007.